Skip to main content
Caplight Logo









Nereid Therapeutics

Nereid Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://nereidtx.com/

Last Round

Series A

Nov 16, 2020

Total Funding Raised

$50M

Company Overview

Nereid Therapeutics is a biotechnology company that develops small molecule therapeutics for cancer, neurodegenerative disorders, and inflammatory diseases by leveraging proprietary technologies to study liquid-liquid phase separation and biomolecular condensates.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biomolecular condensatesdrug discoverysmall-molecule therapeuticsprotein aggregationundruggable targetsbiotechphenotypic screeninghigh-throughput screeningdrug discovery platformmedicinal chemistryoptogenetic assayscondensate biologyphase separationquantitative structure-activity relationshipQSARbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nereid Therapeutics Comparables

Compare Nereid Therapeutics with similar companies based on industry and business-model similarity.

Nereid Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Transition Bio
92%
Dewpoint Therapeutics
91%
Aquinnah Pharmaceuticals
88%

Nereid Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 16, 2020

Nereid Therapeutics Investors

Notable investors and investment history

Nereid Therapeutics investors
InvestorRounds
Apple Tree PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 16, 2020

    $50M round led by Apple Tree Partners

Nereid Therapeutics Filings

Explore SEC and related filing metadata, where available.

Nereid Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nereid Therapeutics's valuation, stock price, and market status.

Is Nereid a public or private company?

Nereid is a private company.

What is the current stock price of Nereid?

Nereid is a private company with no public stock price. No recent secondary market data is available.

How much is Nereid worth (valuation)?

Valuation information for Nereid is not publicly available.

Can I buy Nereid stock?

Nereid shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nereid's last funding round?

Nereid's most recent funding round was Series A on November 16, 2020.

Who are the main investors in Nereid?

Key investors in Nereid include Apple Tree Partners.

Will Nereid IPO soon?

No public IPO plans have been announced for Nereid.

How can I track Nereid secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nereid's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range2
Year Founded2020
Last FundingNov 16, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?